No ocular manifestations associated with inflammatory bowel disease, study finds
August 14, 2022
In a study, investigators found that no characteristics of inflammatory bowel disease are related to ocular manifestations of the disease.
© 2022 MJH Life Sciences™ and Opthalmology Times Europe. All rights reserved.
Retina
Applying cryopreserved amniotic membrane following intravitreal injection
August 15, 2022
CAM encourages corneal healing in patients with ocular surface disease.
Weekly review in ophthalmology: 6-12 August
August 12, 2022
An end-of-week review of what happened in ophthalmology from 6 to 12 August 2022.
A window into the world of academic retina practice today
August 11, 2022
Dr Jayanth Sridhar shares a day in the life of an academic retina specialist.
Intravenous bevacizumab repackaged for intravitreal use: Making the sight-saving treatment safer
August 10, 2022
Although off-label repackaged bevacizumab syringes appear to satisfy an urgent clinical and financial need for patients with a variety of retinal disorders, they are known to be associated with considerable public health concerns due to the risks posed to patients from compounding pharmacies’ lack of compliance with a variety of FDA requirements.
First-ever retinal gene therapy: Does real-world experience back its use?
August 04, 2022
Recent reports of retinal atrophy have raised concerns on potential long-term safety.
Gene fragments may reveal unexplained causes of inherited retinal diseases
July 31, 2022
The findings of this study may have revealed the crucial role of gene fragments in retinal development and vision.
Identifying viral vectors for efficacious gene therapy delivery via computational platform
July 30, 2022
A novel computational platform identifies top-performing viral vectors that could deliver gene therapies to the retina with maximum efficiency and precision.
No additional benefit from atropine to stop axial lengthening
July 27, 2022
No effect when used with orthokeratology lenses for 2 years.
First patient dosed in Phase 2 optogenetic gene therapy clinical trial for Stargardt disease
July 26, 2022
According to the Nanoscope Therapeutics, 6-month safety and efficacy data are expected in Q1 2023. MCO-010 gene therapy reprograms healthy retinal cells to make them photosensitive.